If cancer is found in a prostate biopsy, it is graded in order to estimate how fast it is likely to grow and spread. Prostate cancers are graded according to how closely they look like normal prostate tissue.
The most commonly used prostate cancer grading system is called the Gleason system. This system assigns a Gleason grade ranging from 1 through 5 based on how much the arrangement of the cancer cells mimics the way normal prostate cells from glands. If the cancer cell clusters resemble the small, regular, evenly spaced glands of normal prostate tissue, a grade of 1 is assigned. If the cancer lacks these features and its cells seem to spread haphazardly through the prostate, it is a grade 5 tumour.
Cancers with a high Gleason score are more likely to have already spread beyond the prostate gland at the time they are detected. Therefore, the Gleason score along with the blood PSA level and DRE is useful in considering treatment options.
The big news in oncology has been Johnson and Johnson purchasing Cougar Biotechnology for $1 billion. They have just bought promising prostate cancer compound, abiraterone.
So look out for this oral drug.
Dr.Shroff
The data hasn't even been announced at ASCO yet, that's this weekend coming, so one can only speculate that suitors got a sneak peek of the data under an NDA. A billion dollars certainly gets attention and raises the ante for future small oncology biotech deals.